Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation

Drug and Alcohol Dependence

Volumn 154, Issue , 2015, Pages 278-282

  Chen, Li Shiun ^a,b   Baker, Timothy B ^c   Jorenby, Douglas ^c   Piper, Megan ^c   Saccone, Nancy ^a   Johnson, Eric ^d   Breslau, Naomi ^e   Hatsukami, Dorothy ^f   Carney, Robert M ^a   Bierut, Laura J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d RTI INTERNATIONAL   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CHRNA5; Nicotine replacement therapy; Pharmacogenetic; Smoking cessation; Varenicline

Indexed keywords

PLACEBO; VARENICLINE; CHRNA5 PROTEIN, HUMAN; NERVE PROTEIN; NICOTINE GUM; NICOTINIC RECEPTOR;

ADULT; AGED; ARTICLE; CHRNA5 GENE; CONTROLLED STUDY; GENE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICATION THERAPY MANAGEMENT; MULTICENTER STUDY; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TREATMENT OUTCOME; DRUG THERAPY; FEMALE; GENETIC VARIATION; GENETICS; MALE; MIDDLE AGED; PROCEDURES; SMOKING; YOUNG ADULT;

ADULT; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; RECEPTORS, NICOTINIC; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; VARENICLINE; YOUNG ADULT;

EID: 84938975626     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.06.022     Document Type: Article

References (38)

1. Baker T.B., Weiss R.B., Bolt D., von Niederhausern A., Fiore M.C., Dunn D.M., Piper M.E., Matsunami N., Smith S.S., Coon H., McMahon W.M., Scholand M.B., Singh N., Hoidal J.R., Kim S.Y., Leppert M.F., Cannon D.S. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob. Res. 2009, 11:785-796.
2. Bergen A.W., Javitz H.S., Krasnow R., Nishita D., Michel M., Conti D.V., Liu J., Lee W., Edlund C.K., Hall S., Kwok P.Y., Benowitz N.L., Baker T.B., Tyndale R.F., Lerman C., Swan G.E. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet. Genomics 2013, 23:94-103.
3. Bierut L.J., Stitzel J.A., Wang J.C., Hinrichs A.L., Grucza R.A., Xuei X., Saccone N.L., Saccone S.F., Bertelsen S., Fox L., Horton W.J., Breslau N., Budde J., Cloninger C.R., Dick D.M., Foroud T., Hatsukami D., Hesselbrock V., Johnson E.O., Kramer J., Kuperman S., Madden P.A., Mayo K., Nurnberger J., Pomerleau O., Porjesz B., Reyes O., Schuckit M., Swan G., Tischfield J.A., Edenberg H.J., Rice J.P., Goate A.M. Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry 2008, 165:1163-1171.
4. Brown R.W., Collins A.C., Lindstrom J.M., Whiteaker P. Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. J. Neurochem. 2007, 103:204-215.
5. Cahill K., Stevens S., Perera R., Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst. Rev. 2013, 5:1-44. (CD009329).
6. Chen L.S., Baker T.B., Piper M.E., Breslau N., Cannon D.S., Doheny K.F., Gogarten S.M., Johnson E.O., Saccone N.L., Wang J.C., Weiss R.B., Goate A.M., Bierut L.J. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am. J. Psychiatry 2012, 169:735-742.
7. Chen L.S., Bloom J.A., Baker T.B., Smith S.S., Piper M.E., Martinez M., Saccone N.L., Hatsukami D., Goate A.M., Bierut L.J. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 2014, 109:128-137.
8. Chen L.S., Hung R.J., Baker T., Horton A., Culverhouse R., Saccone N., Cheng I., Deng B., Han Y., Hansen H.M., Horsman J., Kim C., Lutz S., Rosenberger A., Aben K.K., Andrew A.S., Breslau N., Chang S.C., Dieffenbach A.K., Dienemann H., Frederiksen B., Han J., Hatsukami D.K., Johnson E.O., Pande M., Wrensch M.R., McLaughlin J., Skaug V., van der Heijden H.F., Wampfler J., Wenzlaff A., Woll P., Zienolddiny S., Bickeboller H., Brenner H., Duell E.J., Haugen A., Heinrich J., Hokanson J.E., Hunter D.J., Kiemeney L.A., Lazarus P., Le Marchand L., Liu G., Mayordomo J., Risch A., Schwartz A.G., Teare D., Wu X., Wiencke J.K., Yang P., Zhang Z.F., Spitz M.R., Kraft P., Amos C.I., Bierut L.J. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis-a meta-analysis. J. Natl. Cancer Inst. 2015, 107(5):1-9.
9. David S.P., Strong D.R., Leventhal A.M., Lancaster M.A., McGeary J.E., Munafo M.R., Bergen A.W., Swan G.E., Benowitz N.L., Tyndale R.F., Conti D.V., Brown R.A., Lerman C., Niaura R. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 2013, 108:2202-2211.
10. Fiore M.C., Baker T.B. Clinical practice. Treating smokers in the health care setting. N. Engl. J. Med. 2011, 365:1222-1231.
11. Fiore M.C., Jaen C.R., Tb B., et al. Treating Tobacco Use And Dependence: 2008 Update. U.S. Department Of Health And Human Services, U.S 2008, Public Health Service, Rockville, MD.
12. Fowler C.D., Lu Q., Johnson P.M., Marks M.J., Kenny P.J. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
13. Freathy R.M., Ring S.M., Shields B., Galobardes B., Knight B., Weedon M.N., Smith G.D., Frayling T.M., Hattersley A.T. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum. Mol. Genet. 2009, 18:2922-2927.
14. Gold A.B., Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum. Genet. 2012, 131(6):857-876.
15. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
16. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R.N., McAfee T., Peto R. 21st-century hazards of smoking and benefits of cessation in the United States. N. Engl. J. Med. 2013, 368:341-350.
17. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Billing C.B., Gong J., Reeves K.R. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
18. King D.P., Paciga S., Pickering E., Benowitz N.L., Bierut L.J., Conti D.V., Kaprio J., Lerman C., Park P.W. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012, 37:641-650.
19. Knopik V.S., Maccani M.A., Francazio S., McGeary J.E. The epigenetics of maternal cigarette smoking during pregnancy and effects on child development. Dev. Psychopathol. 2012, 24:1377-1390.
20. Liu J.Z., Tozzi F., Waterworth D.M., Pillai S.G., Muglia P., Middleton L., Berrettini W., Knouff C.W., Yuan X., Waeber G., Vollenweider P., Preisig M., Wareham N.J., Zhao J.H., Loos R.J., Barroso I., Khaw K.T., Grundy S., Barter P., Mahley R., Kesaniemi A., McPherson R., Vincent J.B., Strauss J., Kennedy J.L., Farmer A., McGuffin P., Day R., Matthews K., Bakke P., Gulsvik A., Lucae S., Ising M., Brueckl T., Horstmann S., Wichmann H.E., Rawal R., Dahmen N., Lamina C., Polasek O., Zgaga L., Huffman J., Campbell S., Kooner J., Chambers J.C., Burnett M.S., Devaney J.M., Pichard A.D., Kent K.M., Satler L., Lindsay J.M., Waksman R., Epstein S., Wilson J.F., Wild S.H., Campbell H., Vitart V., Reilly M.P., Li M., Qu L., Wilensky R., Matthai W., Hakonarson H.H., Rader D.J., Franke A., Wittig M., Schafer A., Uda M., Terracciano A., Xiao X., Busonero F., Scheet P., Schlessinger D., St Clair D., Rujescu D., Abecasis G.R., Grabe H.J., Teumer A., Volzke H., Petersmann A., John U., Rudan I., Hayward C., Wright A.F., Kolcic I., Wright B.J., Thompson J.R., Balmforth A.J., Hall A.S., Samani N.J., Anderson C.A., Ahmad T., Mathew C.G., Parkes M., Satsangi J., Caulfield M., Munroe P.B., Farrall M., Dominiczak A., Worthington J., Thomson W., Eyre S., Barton A., Mooser V., Francks C., Marchini J. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 2010, 42:436-440.
21. McGeary J.E., Knopik V.S., Hayes J.E., Palmer R.H., Monti P.M., Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. Subst. Abuse 2012, 6:107-114.
22. McMahon F.J., Insel T.R. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron 2012, 74:773-776.
23. Munafo M.R., Johnstone E.C., Walther D., Uhl G.R., Murphy M.F., Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob. Res. 2011, 13:982-988.
24. Piper M.E., Smith S.S., Schlam T.R., Fiore M.C., Jorenby D.E., Fraser D., Baker T.B. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch. Gen. Psychiatry 2009, 66:1253-1262.
25. Ray R., Tyndale R.F., Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J. Neurogenet. 2009, 23:252-261.
26. Rigotti N.A. Smoking cessation in patients with respiratory disease: existing treatments and future directions. Lancet Respir. Med. 2013, 1:241-250.
27. Rose J.E., Behm F.M., Drgon T., Johnson C., Uhl G.R. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol. Med. 2010, 16:247-253.
28. Rutter J.L. Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J. 2006, 8:E174-E184.
29. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O., Swan G.E., Goate A.M., Rutter J., Bertelsen S., Fox L., Fugman D., Martin N.G., Montgomery G.W., Wang J.C., Ballinger D.G., Rice J.P., Bierut L.J. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 2007, 16:36-49.
30. Sarginson J.E., Killen J.D., Lazzeroni L.C., Fortmann S.P., Ryan H.S., Schatzberg A.F., Murphy G.M. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2011, 156B:275-284.
31. Schroeder S.A. New evidence that cigarette smoking remains the most important health hazard. N. Engl. J. Med. 2013, 368:389-390.
32. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet. 2010, 42:441-447. TAG.
33. Thorgeirsson T.E., Gudbjartsson D.F., Surakka I., Vink J.M., Amin N., Geller F., Sulem P., Rafnar T., Esko T., Walter S., Gieger C., Rawal R., Mangino M., Prokopenko I., Magi R., Keskitalo K., Gudjonsdottir I.H., Gretarsdottir S., Stefansson H., Thompson J.R., Aulchenko Y.S., Nelis M., Aben K.K., den Heijer M., Dirksen A., Ashraf H., Soranzo N., Valdes A.M., Steves C., Uitterlinden A.G., Hofman A., Tonjes A., Kovacs P., Hottenga J.J., Willemsen G., Vogelzangs N., Doring A., Dahmen N., Nitz B., Pergadia M.L., Saez B., De Diego V., Lezcano V., Garcia-Prats M.D., Ripatti S., Perola M., Kettunen J., Hartikainen A.L., Pouta A., Laitinen J., Isohanni M., Huei-Yi S., Allen M., Krestyaninova M., Hall A.S., Jones G.T., van Rij A.M., Mueller T., Dieplinger B., Haltmayer M., Jonsson S., Matthiasson S.E., Oskarsson H., Tyrfingsson T., Kiemeney L.A., Mayordomo J.I., Lindholt J.S., Pedersen J.H., Franklin W.A., Wolf H., Montgomery G.W., Heath A.C., Martin N.G., Madden P.A., Giegling I., Rujescu D., Jarvelin M.R., Salomaa V., Stumvoll M., Spector T.D., Wichmann H.E., Metspalu A., Samani N.J., Penninx B.W., Oostra B.A., Boomsma D.I., Tiemeier H., van Duijn C.M., Kaprio J., Gulcher J.R., McCarthy M.I., Peltonen L., Thorsteinsdottir U., Stefansson K. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 2010, 42:448-453.
34. Thun M.J., Carter B.D., Feskanich D., Freedman N.D., Prentice R., Lopez A.D., Hartge P., Gapstur S.M. 50-year trends in smoking-related mortality in the United States. N. Engl. J. Med. 2013, 368:351-364.
35. Uhl G.R., Drgon T., Johnson C., Ramoni M.F., Behm F.M., Rose J.E. Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement. Mol. Med. 2010, 16:513-526.
36. Vaidyanathan G. Redefining clinical trials: the age of personalized medicine. Cell 2012, 148:1079-1080.
37. Whiteford H.A., Baxter A.J. The Global Burden of Disease 2010 study: what does it tell us about mental disorders in Latin America?. Rev. Bras. Psiquiatr. 2013, 35:111-112.
38. Zhu A.Z., Zhou Q., Cox L.S., David S.P., Ahluwalia J.S., Benowitz N.L., Tyndale R.F. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clin. Pharmacol. Ther. 2014, 96:256-265.